Theravance Biopharma’s (TBPH) “Buy” Rating Reiterated at HC Wainwright

HC Wainwright restated their buy rating on shares of Theravance Biopharma (NASDAQ:TBPH) in a research note issued to investors on Tuesday morning,Benzinga reports. They currently have a $15.00 price objective on the biopharmaceutical company’s stock. HC Wainwright also issued estimates for Theravance Biopharma’s Q4 2024 earnings at ($0.17) EPS, FY2024 earnings at ($1.01) EPS, FY2025 earnings at ($0.69) EPS, FY2026 earnings at ($0.42) EPS, FY2027 earnings at ($0.43) EPS, FY2028 earnings at $1.11 EPS and FY2029 earnings at $3.87 EPS.

Theravance Biopharma Stock Up 2.1 %

TBPH opened at $9.27 on Tuesday. Theravance Biopharma has a 52 week low of $7.44 and a 52 week high of $10.90. The business’s 50 day moving average is $9.34 and its two-hundred day moving average is $8.92. The firm has a market cap of $455.84 million, a price-to-earnings ratio of -9.18 and a beta of 0.21.

Theravance Biopharma (NASDAQ:TBPH) last announced its earnings results on Wednesday, February 26th. The biopharmaceutical company reported ($0.31) EPS for the quarter, missing analysts’ consensus estimates of ($0.05) by ($0.26). Theravance Biopharma had a negative net margin of 78.18% and a negative return on equity of 24.79%. The business had revenue of $18.75 million during the quarter, compared to analyst estimates of $29.90 million. Equities analysts expect that Theravance Biopharma will post -1.09 EPS for the current fiscal year.

Insider Activity

In related news, SVP Rhonda Farnum sold 4,000 shares of the business’s stock in a transaction dated Tuesday, January 21st. The stock was sold at an average price of $9.00, for a total value of $36,000.00. Following the transaction, the senior vice president now owns 309,565 shares in the company, valued at $2,786,085. The trade was a 1.28 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website. Corporate insiders own 6.90% of the company’s stock.

Institutional Trading of Theravance Biopharma

Hedge funds have recently added to or reduced their stakes in the stock. Aquatic Capital Management LLC purchased a new stake in shares of Theravance Biopharma during the fourth quarter worth approximately $25,000. KLP Kapitalforvaltning AS acquired a new position in Theravance Biopharma in the 4th quarter valued at $69,000. Quantbot Technologies LP purchased a new position in Theravance Biopharma during the 3rd quarter worth $60,000. China Universal Asset Management Co. Ltd. lifted its stake in shares of Theravance Biopharma by 64.7% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 9,409 shares of the biopharmaceutical company’s stock worth $76,000 after acquiring an additional 3,696 shares during the period. Finally, Teacher Retirement System of Texas purchased a new stake in shares of Theravance Biopharma in the fourth quarter valued at about $103,000. 99.10% of the stock is owned by institutional investors and hedge funds.

Theravance Biopharma Company Profile

Theravance Biopharma, Inc is a diversified biopharmaceutical company primarily focused on the discovery, development and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small molecule drugs designed to better meet patient needs. Its research is focused in the areas of inflammation and immunology.
In pursuit of its purpose, Theravance Biopharma applies insights and innovation at each stage of its business and utilizes its internal capabilities and those of partners around the world.